Vanta BioscienceBOM:540729 +4.98%56 Net Margin % is 127.24% as of Mar. 2026, which is 13882% above its 10-year median of 0.91. GuruFocus rates BOM:540729 with a GF Score™ of 56/100 and a GF Value™ of ₹12.07 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 205 Medical Diagnostics & Research companies, Vanta Bioscience ranks better than 66.34% on this metric.
The historical rank and industry rank for Vanta Bioscience's Net Margin % or its related term are showing as below:
BOM:540729'
s Net Margin % Range Over the Past 10 Years
Min: -236.91 Med: 0.91 Max: 7.1
Current: 5.96
BOM:540729's Net Margin % is ranked better than 66.34% of 205
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.69
vs BOM:540729: 5.96
Vanta Bioscience (BOM:540729) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vanta Bioscience Net Margin % Related Terms
Vanta Bioscience Net Margin % Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540729 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience (BOM:540729) has a Net Margin % of 127.24% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Vanta Bioscience and its competitors. This is 13882% above median its historical median of 0.91. According to the industry distribution chart, Vanta Bioscience ranks #69 out of 205 companies in the Medical Diagnostics & Research industry, placing it in the top 33.7%.
Is Vanta Bioscience's Net Margin % too high?
Vanta Bioscience's current Net Margin % of 127.24% is 13882% above median its 10-year median of 0.91. Based on the distribution chart, Vanta Bioscience ranks #69 out of 205 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Vanta Bioscience has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #69 out of 205 companies for Net Margin %. This puts Vanta Bioscience in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vanta Bioscience and its competitors. Vanta Bioscience's current Net Margin % is 127.24%, which is 13882% above median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.07, compared to a current price of ₹25.29 — trading 109.5% above its estimated fair value. The current Net Margin % is 127.24%, which is 13882% above median its 10-year median of 0.91. Vanta Bioscience's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Net Margin % is 127.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹25.29 is trading 109.5% above its estimated GF Value™ of ₹12.07.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
Net Margin %: 127.24% (13882% above median its 10-year median of 0.91)
GF Value™: ₹12.07 vs. price of ₹25.29 (109.5% above fair value)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
56GF Score
Get the complete analysis for BOM:540729
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
